Paper Details

  1. Home
  2. Paper Details

A selective oral vasopressin V2-receptor antagonist for patients with end-stage liver disease awaiting liver transplantation: a preliminary study.

Author: AkamatsuNobuhisa, AritaJunichi, HasegawaKiyoshi, IshizawaTakeaki, KanekoJunichi, KiritaniSho, KokudoNorihiro, MatsumuraMasaru, MiyataYoichi, TamuraSumihito

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Clinical TrialA clinical trial is a planned study conducted on humans to evaluate the efficacy and safety of pharmaceuticals, medical devices, and treatment methods. It aims to explore the possibilities of new treatments and improve the health of patients.

Overview

This study investigated the safety and efficacy of low-dose tolvaptan, a selective arginine vasopressin V2 receptor antagonist, in patients with far-advanced end-stage liver disease (ESLD) and refractory ascites awaiting liver transplantation. The study found that low-dose tolvaptan was safe and demonstrated favorable effects in 60% of patients.
Paper Details　
Original Abstract of the Article :
Administration of the selective arginine vasopressin V2 receptor antagonist tolvaptan to cirrhotic patients is controversial. There are no reports of tolvaptan use for patients with far-advanced end-stage liver disease (ESLD) and refractory ascites awaiting liver transplantation. Between 2013 and 20...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://doi.org/10.5582/bst.2019.01072

データ提供：米国国立医学図書館（NLM）

Exploring Tolvaptan for Refractory Ascites in End-Stage Liver Disease

End-stage liver disease (ESLD) can lead to a buildup of fluid in the abdomen (ascites), which can be difficult to manage. This study investigated the safety and effectiveness of tolvaptan, a vasopressin V2 receptor antagonist, for patients with refractory ascites awaiting liver transplantation. The researchers enrolled 64 patients and found that low-dose tolvaptan was safe and demonstrated favorable effects in reducing ascites and body weight in some patients.

Tolvaptan Shows Promise in Refractory Ascites

The study suggests that low-dose tolvaptan may be a safe and effective treatment option for patients with refractory ascites in the context of ESLD. The observed weight loss and ascites reduction in some patients highlight the potential of tolvaptan as a therapeutic agent.

Managing Ascites in End-Stage Liver Disease

This study provides important insights into the potential of tolvaptan for managing refractory ascites in patients with ESLD awaiting transplantation. It's like a gentle breeze in the midst of a scorching desert, offering temporary relief and hope for individuals facing a challenging condition.

Dr.Camel's Conclusion

This preliminary study provides valuable insights into the potential of tolvaptan for managing refractory ascites in patients with ESLD. While further research is needed to confirm these findings and explore the optimal dosing and duration of treatment, the study suggests that tolvaptan may offer a safe and effective approach for managing this challenging complication.
Date :
  1. Date Completed 2019-08-30
  2. Date Revised 2021-04-05
Further Info :

Pubmed ID

31019162

DOI: Digital Object Identifier

10.5582/bst.2019.01072

Related Literature

Article Analysis
・Effects of tolvaptan (low blood sodium)
SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.